Global Helicobacter Pylori Tests (In Vitro Diagnostics) Market Analysis and Forecast Report 2020-2030 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Helicobacter Pylori Tests (In Vitro Diagnostics) – Global Market Analysis and Forecast Model (COVID-19 Market Impact)” report has been added to ResearchAndMarkets.com’s offering.

Helicobacter Pylori Tests (In Vitro Diagnostics) – Global Market Analysis and Forecast Model (COVID-19 market impact) is built to visualize quantitative market trends within In Vitro Diagnostics therapeutic area.

The model discusses in detail the impact of COVID-19 on Helicobacter Pylori Tests market for the year 2020 and beyond. H. pylori has been recognized as a Class I carcinogen by the International Agency for Research on Cancer and as one of the strongest known risk factors for gastric malignancies like peptic ulcer disease, gastric MALT lymphoma and gastric cancer as 89% of all gastric cancers are related to H. pylori infection.

The occurrence of infection is mainly observed during childhood in large number of population. It gets transmitted from mother-to-child in developed countries, but horizontal transmission is not observed in developed countries due to better sanitary conditions.

The prevalence is lower in developed nations with a prevalence rate of 15.5% when compared to the developing countries having a prevalence rate of 93.6%. The main causes for the high prevalence of infection are poverty enhanced level of transmission due to malnutrition, poor hygiene and unaffordable heath care indicating low socioeconomic status in regions like Asia, South America and Africa. Helicobacter Pylori Tests is segmented into Helicobacter pylori Breath Test, Helicobacter pylori Feces Test, Helicobacter pylori IHC Test, Helicobacter pylori Serology EIA Test, Helicobacter Pylori Point of Care (POC) Tests and Helicobacter Pylori Other Tests.

Scope

• CMO executives who must have deep understanding of the Helicobacter Pylori Tests market place to make strategic planning and investment decisions.
• Sourcing and procurement executives who must understand crucial components of the supply base in order to make decisions about supplier selection and management.
• Private equity investors that need a deeper understanding of the market to identify and value potential investment targets.

Reasons to Buy

• Understand the impact of COVID-19 on Helicobacter Pylori Tests market.
• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving Helicobacter Pylori Tests market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the Helicobacter Pylori Tests market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the company share of market leaders.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Track device sales in the global and country-specific Helicobacter Pylori Tests market from 2015-2030.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Companies Mentioned

• Avanos Medical Inc
• Otsuka Holdings Co Ltd
• Meridian Bioscience Inc
• DiaSorin SpA
• F. Hoffmann-La Roche Ltd
• Thermo Fisher Scientific Inc
• bioMerieux SA
• Bio-Rad Laboratories Inc
• Siemens Healthineers AG
• Trinity Biotech Plc
• Merck KGaA
• Sekisui Chemical Co Ltd

For more information about this report visit https://www.researchandmarkets.com/r/3wkhg3

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900